NizarM.TannirMD

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston Deputy Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The Univer

Join to view full profile

Dr. Tannir is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tannir's full profile

Already have an account?

Office
1515 Holcombe Blvd
UT MD Anderson Cancer Center, Unit 1374
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Muhlenberg Regional Medical CenterResidency, Internal Medicine, 1984 - 1985
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
American University of Beirut Faculty of MedicineClass of 1979

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1984 - 2027
OK State Medical License 2020 - 2021
KY State Medical License 1987 - 2015
NJ State Medical License 1985 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
Pemetrexed Plus Gemcitabine in Renal Cell Cancer Start of enrollment: 2005 Dec 01
Terminated
Phase 2
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) Start of enrollment: 2010 May 01
Completed
Phase 1
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial Start of enrollment: 2011 Jan 19
ACTIVE_NOT_RECRUITING
PHASE2
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Start of enrollment: 2012 Oct 24
Completed
Phase 2
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Start of enrollment: 2015 Dec 22
COMPLETED
PHASE2
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer Start of enrollment: 2017 Apr 23
COMPLETED
PHASE1, PHASE2
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma Start of enrollment: 2017 Dec 13
ACTIVE_NOT_RECRUITING
PHASE2
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2018 Aug 17
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.
Axel Bex, Michael Jewett, Bryan Lewis, E Jason Abel, Laurence Albiges
European Urology. 2025-04-01
2 citations
Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.
Justin M Lebenthal, Panayiotis D Kontoyiannis, Andrew W Hahn, Zita D Lim, Priya Rao
European Urology Oncology. 2025-04-01
TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma.
Alexandra Helleux, Guillaume Davidson, Antonin Lallement, Fatima Al Hourani, Alexandre Haller
EMBO Molecular Medicine. 2025-03-27

Lectures

A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with pre...
2019 ASCO Annual Meeting - 6/1/2019
Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

MD Anderson Research Highlights for February 26, 2025February 26th, 2025
MD Anderson Unveils Groundbreaking Research Breakthroughs – February 26, 2025February 26th, 2025
CAR T-cell Therapy for Kidney Cancer Builds on Efficacy RecordNovember 9th, 2024
Join now to see all